In the past 10 years, the realization that migraine is a brain disorder rather than a vascular disorder has facilitated development of various treatments, ranging from innovative immunopharmaceuticals through to neurostimulation. Many clinical trials have been successful, and such considerable progress holds promise for the coming decade of migraine treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743–800 (2015).
Amin, F. M. et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 12, 454–461 (2013).
Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C. & Goadsby, P. J. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137, 232–241 (2014).
Hougaard, A., Amin, F., Hauge, A. W., Ashina, M. & Olesen, J. Provocation of migraine with aura using natural trigger factors. Neurology 80, 428–431 (2013).
Akerman, S., Holland, P. & Goadsby, P. J. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 12, 570–584 (2011).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193–196 (1988).
Ho, T. W., Edvinsson, L. & Goadsby, P. J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6, 573–582 (2010).
Ayata, C., Jin, H., Kudo, C., Dalkara, T. & Moskowitz, M. A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652–661 (2006).
Tolner, E. A. et al. From migraine genes to mechanisms. Pain 156 (Suppl. 1), S64–S74 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received grants and personal fees from Allergan, Amgen and eNeura, and personal fees from Ajinomoto Pharmaceuticals, Akita Biomedical, Alder Biopharmaceuticals, Autonomic Technologies, Avanir Pharmaceuticals, Cipla, CoLucid Pharmaceuticals, Dr Reddy's Laboratories, EMKinetics, Ethicon, Heptares, Lilly, NEJM Journal Watch, Pfizer, Promius Pharma, Teva, UpToDate, Wells Fargo, W. L. Gore & Associates and Zosano Pharma. He has also received personal fees for medicolegal work for individuals. He also has a patent pending for magnetic stimulation for headache.
Supplementary information
Supplementary Table 1
Migraine therapeutics that have been tested in clinical trials (DOC 143 kb)
Rights and permissions
About this article
Cite this article
Goadsby, P. Incredible progress for an era of better migraine care. Nat Rev Neurol 11, 621–622 (2015). https://doi.org/10.1038/nrneurol.2015.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.203
- Springer Nature Limited
This article is cited by
-
Anxiety and depression symptoms and migraine: a symptom-based approach research
The Journal of Headache and Pain (2017)